ATE376824T1 - Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln - Google Patents

Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln

Info

Publication number
ATE376824T1
ATE376824T1 AT00902481T AT00902481T ATE376824T1 AT E376824 T1 ATE376824 T1 AT E376824T1 AT 00902481 T AT00902481 T AT 00902481T AT 00902481 T AT00902481 T AT 00902481T AT E376824 T1 ATE376824 T1 AT E376824T1
Authority
AT
Austria
Prior art keywords
hyaluronan
effectiveness
medication
producing
increase
Prior art date
Application number
AT00902481T
Other languages
English (en)
Inventor
Tracey Brown
Original Assignee
Alchemia Oncology Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP8131A external-priority patent/AUPP813199A0/en
Priority claimed from AUPQ3938A external-priority patent/AUPQ393899A0/en
Application filed by Alchemia Oncology Pty Ltd filed Critical Alchemia Oncology Pty Ltd
Application granted granted Critical
Publication of ATE376824T1 publication Critical patent/ATE376824T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT00902481T 1999-01-13 2000-01-06 Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln ATE376824T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP8131A AUPP813199A0 (en) 1999-01-13 1999-01-13 A composition and method for the enhancement of the efficacy of drugs
AUPQ3938A AUPQ393899A0 (en) 1999-11-09 1999-11-09 A composition and method for the enhancement of the efficacy of drugs

Publications (1)

Publication Number Publication Date
ATE376824T1 true ATE376824T1 (de) 2007-11-15

Family

ID=25645970

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00902481T ATE376824T1 (de) 1999-01-13 2000-01-06 Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln

Country Status (14)

Country Link
US (1) US8741970B2 (de)
EP (1) EP1140198B1 (de)
JP (2) JP4790911B2 (de)
KR (1) KR20010113642A (de)
CN (1) CN100374163C (de)
AT (1) ATE376824T1 (de)
CA (1) CA2370003C (de)
DE (1) DE60036915T2 (de)
DK (1) DK1140198T3 (de)
ES (1) ES2295005T3 (de)
HK (1) HK1041209A1 (de)
NZ (1) NZ512676A (de)
TW (1) TWI284042B (de)
WO (1) WO2000041730A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ512676A (en) 1999-01-13 2003-01-31 Meditech Res Ltd A composition and method for the enhancement of the efficacy of drugs
US7582311B1 (en) * 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
US7125858B2 (en) 1999-12-28 2006-10-24 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
EP1443931B1 (de) * 2001-07-20 2007-03-28 Iomed, Inc. Iontophoretische okularvorrichtung zur abgabe von medikamenten auf methotrexat-basis und deren verwendung zur behandlung von neoplastischen, angiogenen, fibroplastischen und/oder immunsuppressiven augenunregelmässigkeiten
JP2005505540A (ja) * 2001-08-27 2005-02-24 メディテック　リサーチ　リミテッド 改善された治療プロトコール
AU2002325635C1 (en) * 2001-08-27 2008-09-25 Alchemia Oncology Pty Limited Improved therapeutic protocols
KR20030066927A (ko) * 2002-02-06 2003-08-14 구자영 쿠르쿠민과 5-프루오로유라실로 이루어진 항암제 및 이항암제의 용도
CA2513143A1 (en) 2002-07-01 2004-01-08 Tufts University Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers
ITPD20020271A1 (it) 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
EP1569616A2 (de) 2002-12-04 2005-09-07 Technologies Biolactis Inc. Exopolysaccharide darreichungsform für aktive molekülen
KR20160014775A (ko) 2003-05-30 2016-02-11 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
CN101287474B (zh) 2005-07-27 2014-08-20 阿尔卡米亚肿瘤学股份有限公司 使用乙酰透明质酸的治疗方案
MY149606A (en) 2005-09-07 2013-09-13 Alchemia Oncology Pty Ltd Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment
KR20110056042A (ko) * 2009-11-20 2011-05-26 주식회사유한양행 종양세포 표적지향을 위한 나노 입자 및 이의 제조방법
US11672866B2 (en) 2016-01-08 2023-06-13 Paul N. DURFEE Osteotropic nanoparticles for prevention or treatment of bone metastases
US11344629B2 (en) 2017-03-01 2022-05-31 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
US12252708B2 (en) 2018-09-24 2025-03-18 Unm Rainforest Innovations Living mammalian cells modified with functional modular nanoparticles
US12208164B2 (en) 2019-02-28 2025-01-28 Unm Rainforest Innovations Modular metal-organic polyhedra superassembly compositions

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA612307A (en) 1961-01-10 International Business Machines Corporation Hydraulic drive tape handling system
US4141973A (en) 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
IT1229075B (it) 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
US5166331A (en) 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
FR2553099B1 (fr) 1983-10-11 1989-09-08 Fidia Spa Fractions d'acide hyaluronique ayant une activite pharmaceutique, procedes pour leur preparation et compositions pharmaceutiques les contenant
JPS6117A (ja) 1984-06-11 1986-01-06 Seikagaku Kogyo Co Ltd ムコ多糖系癌転移抑制剤
CA1227427A (en) * 1984-08-16 1987-09-29 Albert Landsberger Therapeutic agent for the use in cancer treatment
US5532341A (en) 1985-03-28 1996-07-02 Sloan-Kettering Institute For Cancer Research Human pluripotent hematopoietic colony stimulating factor
US5202431A (en) 1985-07-08 1993-04-13 Fidia, S.P.A. Partial esters of hyaluronic acid
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US4665107A (en) 1986-03-21 1987-05-12 Koh-I-Noor Rapidograph, Inc. Pigment encapsulated latex aqueous colorant dispersions
IT1198449B (it) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
IT1219587B (it) 1988-05-13 1990-05-18 Fidia Farmaceutici Polisaccaridi carbossiilici autoreticolati
US5128450A (en) 1989-06-30 1992-07-07 Urdal David L Nonglycosylated human interleukin-3 analog proteins
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5095037B1 (en) 1989-12-21 1995-12-19 Nissho Kk Combined anti-inflammatory agent
CA2061566C (en) 1992-02-20 2002-07-09 Rudolf E. Falk Treatment of disease employing hyaluronic acid and nsaids
CA2061703C (en) 1992-02-20 2002-07-02 Rudolf E. Falk Formulations containing hyaluronic acid
US5733891A (en) * 1990-10-18 1998-03-31 Shiseido Co., Ltd. Compound for medicinal ingredient and hyaluronic acid and process for producing the same
US5416071A (en) 1991-03-12 1995-05-16 Takeda Chemical Industries, Ltd. Water-soluble composition for sustained-release containing epo and hyaluronic acid
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
CA2268476A1 (en) 1991-07-03 1998-04-30 Hyal Pharmaceutical Corporation Use of hyaluronan in gene therapy
US5977088A (en) 1991-07-03 1999-11-02 Hyal Pharmaceutical Corporation Formulations containing hyaluronic acid
CA2122519C (en) 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
DK0563475T3 (da) 1992-03-25 2000-09-18 Immunogen Inc Konjugater af cellebindende midler og derivater af CC-1065
CA2153661A1 (en) 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
CA2087621C (en) 1993-01-18 1996-08-20 Albin L. Vazza Livestock feed from potato waste
CA2089621A1 (en) * 1993-02-16 1994-08-17 Rudolf Edgar Falk Formulations containing hyaluronic acid
CA2094203A1 (en) 1993-04-16 1994-10-17 Derek A. Willoughby Inhibition of angiogenesis
US5847002A (en) 1993-04-16 1998-12-08 Hyal Pharmaceutical Corporation Compositions, for inhibition, control and regression of angiogenesis, containing hyaluronic acid and NSAID
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
ITPD940054A1 (it) 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
AU2479695A (en) 1994-05-09 1995-11-29 Hadasit Medical Research Services & Development Company Ltd Prevention of tumor metastasis
IL114914A0 (en) * 1994-08-30 1995-12-08 Hyal Pharma Corp Modulation of cellular activity
AU718451B2 (en) 1995-09-14 2000-04-13 Bristol-Myers Squibb Company Insulin-like growth factor binding protein 3 (IGF-BP3) in treatment of P53-related tumors
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
JP2000513707A (ja) 1995-12-01 2000-10-17 ハイアル ファーマスティカル コーポレイション 投与薬剤の目標化、治療薬および他のグリコサミノグリカン（ｇａｇｓ）
US5776925A (en) 1996-01-25 1998-07-07 Pharmacyclics, Inc. Methods for cancer chemosensitization
DE69700887T2 (de) 1996-01-31 2000-06-29 Nisshin Flour Milling Co., Ltd. Isoprenderivate
AUPN814496A0 (en) 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
KR100236771B1 (ko) 1997-04-01 2000-02-01 성재갑 히아루론산을 이용한 약물의 서방성 미세입자 제형
CA2175282A1 (en) 1996-04-29 1997-10-30 Rudolf Edgar Falk Use of forms of hyaluronic acid (ha) for the treatment of cancer
US5756537A (en) 1996-11-08 1998-05-26 Parkash S. Gill, M.D., Inc. Regime for paclitaxel in Kaposi's sarcoma patients
IT1286510B1 (it) * 1996-11-29 1998-07-15 Cooperativa Centro Ricerche Po Esteri butirrici ad attivita' antiproliferativa e composizioni farmaceutiche che li contengono
EP0891775A4 (de) 1996-12-27 2002-07-24 Seikagaku Kogyo Co Ltd Heilmittel gegen harnblasenstoerungen
DK0971961T3 (da) 1997-04-04 2003-03-24 Fidia Advanced Biopolymers Srl N-sulfaterede hyaluronsyreforbindelser, derivater deraf og en fremgangsmåde til deres fremstilling
CA2208924A1 (en) * 1997-07-09 1999-01-09 Hyal Pharmaceutical Corporation Sparing paclitaxel by the use of hyaluronan
US6087350A (en) 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
GB9727524D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Synergistic antitumor composition containing a biologically active ureido compound
US20020015724A1 (en) 1998-08-10 2002-02-07 Chunlin Yang Collagen type i and type iii hemostatic compositions for use as a vascular sealant and wound dressing
AU6285999A (en) 1998-10-02 2000-04-26 Genzyme Corporation Prevention of adhesions
IT1303735B1 (it) 1998-11-11 2001-02-23 Falorni Italia Farmaceutici S Acidi ialuronici reticolati e loro usi medici.
NZ512676A (en) 1999-01-13 2003-01-31 Meditech Res Ltd A composition and method for the enhancement of the efficacy of drugs
EP1044977B1 (de) 1999-03-09 2002-05-02 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Camptothecin-Derivate mit Antitumor-Wirkung
IT1306643B1 (it) 1999-04-08 2001-10-02 Fidia Advanced Biopolymers Srl Processo per la preparazione dei composti autoreticolati dell'acidoialuronico e dei suoi derivati ottenibili mediante la tecnica
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
SE9904121D0 (sv) 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
US7125858B2 (en) 1999-12-28 2006-10-24 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
US6749865B2 (en) 2000-02-15 2004-06-15 Genzyme Corporation Modification of biopolymers for improved drug delivery
US9066919B2 (en) 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
EP1368309B2 (de) 2001-02-22 2014-10-01 Anika Therapeutics Inc. Thiol-modifizierte hyaluronan-derivate
JP2005505540A (ja) 2001-08-27 2005-02-24 メディテック　リサーチ　リミテッド 改善された治療プロトコール
EP1480656A4 (de) 2002-02-15 2007-07-18 Res Dev Foundation Hyaluronsäure-vermittelte adenovirus-transduktion
JP2004262777A (ja) 2003-02-27 2004-09-24 Shiseido Co Ltd アセチル化ヒアルロン酸含有眼用医薬組成物
US7183381B2 (en) 2004-10-26 2007-02-27 Agennix, Inc. Composition of lactoferrin related peptides and uses thereof
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
CN101287474B (zh) 2005-07-27 2014-08-20 阿尔卡米亚肿瘤学股份有限公司 使用乙酰透明质酸的治疗方案
MY149606A (en) 2005-09-07 2013-09-13 Alchemia Oncology Pty Ltd Therapeutic compositions comprising hyaluronan and therapeutic antibodies as well as methods of treatment

Also Published As

Publication number Publication date
JP2011178802A (ja) 2011-09-15
DK1140198T3 (da) 2008-03-10
HK1041209A1 (zh) 2002-07-05
CN100374163C (zh) 2008-03-12
DE60036915T2 (de) 2008-08-07
JP4790911B2 (ja) 2011-10-12
ES2295005T3 (es) 2008-04-16
CA2370003C (en) 2008-08-19
NZ512676A (en) 2003-01-31
JP2002534484A (ja) 2002-10-15
US20130197103A1 (en) 2013-08-01
KR20010113642A (ko) 2001-12-28
CA2370003A1 (en) 2000-07-20
US8741970B2 (en) 2014-06-03
EP1140198A1 (de) 2001-10-10
EP1140198A4 (de) 2004-08-04
CN1336828A (zh) 2002-02-20
DE60036915D1 (de) 2007-12-13
EP1140198B1 (de) 2007-10-31
WO2000041730A1 (en) 2000-07-20
TWI284042B (en) 2007-07-21

Similar Documents

Publication Publication Date Title
ATE376824T1 (de) Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
WO2005051429A3 (en) Targeted conjugates with a modified saccharide linker
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
DE60203260D1 (de) Pharmazeutische mischung gegen krebs, die ein 4-chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält
EA200501810A1 (ru) Композиция конъюгированного лекарственного средства
WO2005027842A8 (en) Combinations of drugs for the treatment of neoplasms
MXPA02010801A (es) Agentes diagnosticos, de representacion y terapeuticos cationicos asociados con sitios vasculares activados.
BR9709942A (pt) Uso de um composto composição farmacêutica embalagem e processo de tratamento de organismo de animal humano ou não humano para combater ou prevenircondições associadas com a presença de radicais livres no organismo
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
WO2003049694A3 (en) Methods of therapy for non-hodgkin's lymphoma
BR0313116A (pt) Método para a produção de um efeito redutor de permeabilidade vascular e/ou antiangiogênico em um animal de sangue quente tal como um humano, método para o tratamento de um câncer em um animal de sangue quente tal como humano, e, uso de zd6474 ou de um seu sal farmaceuticamente aceitável.
AUPQ879500A0 (en) Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
KR960700734A (ko) 사람 암에 대한 시스플래틴/타목시펜 배합 치료(Combination cisplatin/tamoxifen therapy for human cancers)
ATE247965T1 (de) Paracetamol und buspiron enthaltende pharmazeutische zusammensetzung mit analgetischer wirkung
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
EP1374873B8 (de) Verwendung von n-acetyl-d-glucosamin bei der herstellung eines arzneimittels zur unterdrückung der nebenwirkungen von strahlentherapie und chemotherapie
ZA200605900B (en) Glycosylated steroid derivatives with anti-migratory activity
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
WO2002067954A3 (de) Verwendung des partikulären biokomplexes bk-riv zur herstellung eines arzneimittels zum schutz und zur rekonstruktion des leberparenchyms
BRPI0416019A (pt) uso de siramesina ou de um seu sal farmaceuticamente aceitável, composição farmacêutica, kit, e, método para o tratamento de cáncer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140198

Country of ref document: EP